SecBot SecBot

VTRS

Viatris Inc
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001792044 Biotech & Drug Discovery
$20.49 −0.25 (−1.23%)
Nov 17 4:00 PM ET · prev $20.74
Market cap
$23.9B
Large cap
Consensus
Buy
67% Buy or better · 18 analysts
Median target
🔒 Subscribers only
1 year
+92.2%
from $10.66 · Nov 17
30 days
+12.2%
from $18.26
52-week range
$10.19–21.06
−3% from high · low Nov 20
Avg volume 20D
9.23M
shares / day
Short interest
35.24M
≈3.1% of shares · −7.1%
Days to cover
4.0
at average volume
Insider net
−$1.1M
0 buyers · 1 seller · since Mar 6
New fund stakes
3
Q3 2026 13F · 0 exits
Filing reports
18
analyzed by SecBot
SecBot read BULLISH 10 reports · 90 days
Balance 0 bearish · 4 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 7/10 ·Next FDA decision date, Dec 27, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $1.1M.

  • InstitutionsBULLISH

    Q3 2026: 55 added (3 new), 24 trimmed or exited. Largest new: Sound Shore Management /Ct/ $81.3M.

  • AnalystsBULLISH

    12 of 18 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −7.1% to 35.24M shares. 4.0 days to cover, ≈3.1% of shares.

  • TrendUPTREND

    12% above its 50-day average. New closing high $21.06 on Nov 11.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 30.

Who's buying

13F· Q3 2026
3
new positions
0
exits
$81.3M
in new stakes · top 1 shown
FundMoveSharesValue
FMR LLCADD133,573,736$2.4B
DIMENSIONAL FUND ADVISORS LPTRIM17,201,193$304.9M
Assenagon Asset Management S.A.DOUBLED10,533,840$186.7M
CITIGROUP INCADD6,138,865$108.8M
SOUND SHORE MANAGEMENT INC /CT/NEW4,587,648$81.3M
VICTORY CAPITAL MANAGEMENT INCADD4,029,924$71.4M
Qube Research & Technologies LtdTRIM3,750,949$66.5M
FIRST TRUST ADVISORS LPDOUBLED3,639,592$64.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 67% rate it Buy or better
Strong Buy6Buy6Hold5Sell1Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 17, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 16, 2026Barclays
MAINTAIN
MAINTAINOverweight
Nov 6, 2026JP Morgan
MAINTAIN
MAINTAINNeutral
Oct 26, 2026Piper Sandler
MAINTAIN
MAINTAINNeutral
Oct 21, 2026JP Morgan
MAINTAIN
MAINTAINNeutral
Oct 5, 2026UBS
MAINTAIN
MAINTAINBuy
Congressional trades
VTRS trades disclosed by members of Congress, with disclosure delay.
1 members · 0 buys / 1 sells
DateMemberType AmountDisclosed
May 27, 2026 Ro KhannaDHouse Spouse account · Viatris Inc SELL $1K–$15K Jun 9, 2026 +13d

Insider ledger

Form 4
$0
bought · 0 insiders
$1.1M
sold · 1 insider
DateInsiderTypeValue
Sep 30, 2026
SIMMONS DAVID S
Director
Sep 30, 2026
AWARD$37.5K
Sep 30, 2026
Groothuis Leo Frans
Director
Sep 30, 2026
AWARD$43.8K
Aug 15, 2026
Enrietti Andrew
See Remarks
Aug 15, 2026
EXERCISE25,134 sh
Aug 15, 2026
Enrietti Andrew
See Remarks
Aug 15, 2026
EXERCISE999 sh
Aug 15, 2026
Enrietti Andrew
See Remarks
Aug 15, 2026
EXERCISE998.364 sh
Aug 15, 2026
Enrietti Andrew
See Remarks
Aug 15, 2026
TAX W/H$7.1K
Aug 15, 2026
Enrietti Andrew
See Remarks
Aug 15, 2026
TAX W/H$177.4K
Jun 30, 2026
Groothuis Leo Frans
Director
Jun 30, 2026
AWARD$43.8K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

39 lobbying filings and 12 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
35,240,834
shares short
-7.1%
vs prior settlement
4.0
days to cover
≈3.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 17, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 17, 2026 Press
🔒 Fresh report (last 24h), subscribers only
Nov 17, 2026 M&A
🔒 Fresh data, subscribers only
Nov 16, 2026 SEC
T. Rowe Price Associates filed an amended Schedule 13G disclosing a 5.1% passive stake in Viatris as of September 30…
SC 13G/A · Impact 2/10
Nov 6, 2026 SEC
Davis Selected Advisers filed an amended Schedule 13G disclosing a 6.3% passive stake in Viatris as of September 30…
SC 13G/A · Impact 2/10
Nov 4, 2026 Press
Viatris declared a quarterly dividend of $0.12 per share, payable December 16, 2026, to shareholders of record as of…
Impact 2/10
Sep 30, 2026 Insider
SIMMONS DAVID S was granted 2,117 shares
Director @ $17.72 ($37.5K)
Sep 30, 2026 Insider
Groothuis Leo Frans was granted 2,469 shares
Director @ $17.72 ($43.8K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Upcoming
Recent
Nov 17, 2026
M&A
🔒 Fresh data, subscribers only
Nov 16, 2026
Press release
CADILLAC FORMULA 1® TEAM WELCOMES VIATRIS AS OFFICIAL GLOBAL PHARMACEUTICAL PARTNER
Multiyear partnership brings together a U.S.-based global healthcare company and America's new Formula 1® team INDIANAPOLIS and PITTSBURGH, Nov. 16…
Nov 16, 2026
Clinical Trial
Dexmedetomidine in Postoperative Analgesia
Phase 3 · COMPLETED
Nov 16, 2026
Clinical Trial
Dexmedetomidinine in the Prevention of Postoperative Delirium in the Intensive Care Unit After Cardiac Surgery
Phase 3 · COMPLETED
Nov 12, 2026
Press release
Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive Year
PITTSBURGH, Nov. 12, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to…

SecBot reports

18 filings · 4 press releases · 6 bullish · 1 bearish · 3 mixed · 8 neutral
All VTRS filing & press-release reports (22)